Photostimulation of brain lymphatics in male newborn and adult rodents for therapy of intraventricular hemorrhage.
Dongyu Li, Shaojun Liu, Tingting Yu...
https://pubmed.ncbi.nlm.nih.gov/37775549/Actively Recruiting
Led by Rutgers, The State University of New Jersey · Updated on 2025-07-22
24
Participants Needed
2
Research Sites
56 weeks
Total Duration
Researchers are evaluating the feasibility of a light therapy device called EFIL for treating newborns with severe intraventricular hemorrhage IVH grades 3 and 4. This pilot study aims to assess the safety of the treatment, how well parents accept it, recruitment and consent process, retention rates, and to help design a larger future trial. The study will also track developmental milestones up to 12 months of age to better understand the interventions effects. The treatment involves using a novel laser device that emits 650nm light at an irradiance of 10 mWcm2. Newborn participants will receive the light therapy for 5 minutes twice a day over 12 days. This is an open-label study with one experimental group receiving the laser treatment. Parents will be contacted at 6 and 12 months after treatment to monitor developmental progress. During the study, researchers will conduct regular head ultrasounds weekly up to 4 months old to measure hemorrhage resorption rate, ventricle volume using anterior horn width and ventricular index, and head circumference daily up to 4 months. Neurosurgical interventions will also be tracked from birth to 4 months. The study will last through these assessments and follow-ups to gather information on safety, treatment effects, and developmental outcomes.
CONDITIONS
Light Therapy Device for Neonatal Intraventricular Hemorrhage Grade 3 and 4
G
Garrett Gianneschi, Medical
O
Onajovwe Fofah, Medical
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Rutgers, The State University of New Jersey
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Low Level Laser Therapy Device | Current Standard Care |
|---|---|---|
| What it is | A novel device delivering low level (650nm) laser therapy, given to neonates with grade 3 or 4 intraventricular hemorrhage, twice daily for 12 days. | Current care involves neuromonitoring, supportive intensive care, repeated cranial ultrasounds, management of intracranial pressure and hydrocephalus, and neurosurgical intervention as indicated. |
| Role in trial | Investigational therapy tested for feasibility and clinical effect in neonates with severe IVH. | Represents established standard practice prior to trial enrollment. |
| Primary use | Studied for its ability to enhance hemorrhage resorption, reduce need for neurosurgical intervention, and improve early neurodevelopment after severe IVH. | Aims to manage acute complications, lower intracranial pressure, surveil for hydrocephalus, and support neurodevelopmental outcomes. |
| How it is given or performed | Laser output of 10 mW/cm² at 650nm, applied through the scalp for 5 minutes twice daily over 12 days. | Measures include supportive intensive care, head ultrasound monitoring, and neurosurgical procedures as needed (e.g., ventricular reservoir or shunt). |
| Evidence status | Effectiveness and clinical outcomes not yet established in humans for this indication. Animal studies support biological rationale; first-in-human data limited to feasibility and safety. | Clinical practice supported by observational studies and experience; no established therapy for reliably reversing severe IVH but supportive care and neurosurgical intervention reduce mortality and manage hydrocephalus. |
| Important limitations | Human efficacy and long-term safety have not been determined for this device in neonates with severe IVH. Existing data are from preclinical models and early feasibility studies. | Supportive management and neurosurgical intervention do not repair underlying hemorrhage; most survivors remain at risk for neurodevelopmental impairment. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - Up to 1 month
Participants are screened for eligibility to participate in the trial.
Duration - 12 days
Participants receive light therapy using a novel laser device for 5 minutes twice daily for 12 days.
Twice daily sessions for 12 days
Duration - Up to 4 months
Participants undergo weekly head ultrasounds and daily head circumference measurements to track hemorrhage resorption and ventricle volume up to 4 months old.
Weekly head ultrasounds and daily measurements
Duration - From 6 to 12 months of age
Neurodevelopmental outcomes are assessed at 6 months and 12 months of age.
2 assessment visits
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Dongyu Li, Shaojun Liu, Tingting Yu...
https://pubmed.ncbi.nlm.nih.gov/37775549/Branko N Huisa, Andrew B Stemer, Michael G Walker...
https://pubmed.ncbi.nlm.nih.gov/22299818/Yair Lampl, Justin A Zivin, Marc Fisher...
https://pubmed.ncbi.nlm.nih.gov/17463313/A L Kent, M Broom, V Parr...
https://pubmed.ncbi.nlm.nih.gov/25695843/Margaret A Naeser, Anita Saltmarche, Maxine H Krengel...
https://pubmed.ncbi.nlm.nih.gov/21182447/Justin A Zivin, Gregory W Albers, Natan Bornstein...
https://pubmed.ncbi.nlm.nih.gov/19233936/Rutgers, The State University of New Jersey
Lead Sponsor